semaglutide injections camas Flex-Dose 2 mL Injectable 2.5 mg/mL Semasize CFA Distributors Retailers |

10.1186/s13018-019-1242-6 86 PetekM.SikiricP.AnicT.BuljatG.SeparovicJ.Stancic-RokotovD.et al (1999)

Theres currently a randomized controlled trial on tirzepatide as a potential treatment for sleep apnea

Its exhausting when symptoms persist, and clinicians seem unconvinced

In a head-to-head open-label trial reported in February 2026, average weight loss at 84 weeks favored tirzepatide, and the sponsor noted CagriSema did not meet its prespecified non-inferiority target against tirzepatide

If you are unsure what to do or have missed multiple doses, contact your GP or diabetes specialist nurse for personalised advice